Drug Search Results
More Filters [+]

APR-TD011

Alternative Names: APR-TD011, APRTD011, APR TD011
Latest Update: 2024-10-07
Latest Update Note: Clinical Trial Update

Product Description

APR-TD011 is a wound cleansing spray being developed by Applied Pharma Research for the treatment of epidermolysis bullosa. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05533866?term=APR-TD011&draw=2&rank=1)

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: N/A

FDA Designation: Orphan Drug - Phenylketonurias *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Applied Pharma Research
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for APR-TD011

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: T-Cell Peripheral Lymphoma|T-Cell Cutaneous Lymphoma|Epidermolysis Bullosa, Junctional

Phase 1: Epidermolysis Bullosa

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STU00217913

P1

Not yet recruiting

T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma

2026-12-01

NCT05533866

P1

Active, not recruiting

Epidermolysis Bullosa, Junctional

2024-09-24

Recent News Events